文献速递慢性肾脏病急性肾损伤血液净化与透析

高敏C反应蛋白与中重度慢性肾脏病成人心肾结局风险:一项全国性研究

High sensitivity C-reactive protein and the risk of cardio-kidney outcomes in adults with moderate to severe chronic kidney disease: a nationwide study.
PubMed 文献 · Nephrol Dial Transplant · 2026-10-16

该观察性全国性研究纳入瑞典肾脏登记中23,008例CKD 3-5期成人,通过94,500次重复hsCRP测量评估炎症与心肾结局的关联。中位hsCRP为4.0 mg/L,75%参与者hsCRP≥2 mg/L;hsCRP≥2 mg/L与MACE、心衰住院、AKI、KFRT及全因死亡风险升高相关。

要点

  • 中重度CKD患者炎症普遍,75%参与者hsCRP≥2 mg/L。
  • hsCRP≥2 mg/L与MACE、心衰住院、AKI和死亡风险升高独立相关。
  • hsCRP与KFRT关联较弱且在不同CKD分期中不一致。

核心结论

  • 在中重度CKD成人中,炎症常见,较高hsCRP水平与不良心血管和肾脏结局及死亡相关。

研究设计与样本

  • 观察性全国性研究,纳入瑞典肾脏登记2008-2023年23,008例CKD 3-5期成人,通过94,500次重复hsCRP测量纵向评估炎症。

主要发现

  • 中位hsCRP为4.0(IQR 1.9-7.0)mg/L,75%参与者hsCRP≥2 mg/L。
  • 中位随访3.9(IQR 2.0-6.7)年,hsCRP≥2 mg/L与MACE风险比1.20(95%CI 1.12-1.28;n=5,480事件)相关。
  • hsCRP≥2 mg/L与心衰住院风险比1.29(95%CI 1.22-1.37;n=8,173)、AKI风险比1.28(95%CI 1.18-1.38;n=3,943)相关。
  • hsCRP≥2 mg/L与KFRT风险比1.09(95%CI 1.02-1.15;n=6,177)、全因死亡风险比1.43(95%CI 1.37-1.50;n=12,645)相关。
  • 样条分析显示除KFRT外,各结局在较低hsCRP水平关联更陡峭,之后趋于平坦。

关键数值与推荐

  • hsCRP≥2 mg/L为暴露分组阈值,与所有结局风险升高相关。
  • MACE、心衰、AKI和死亡的关联不受ASCVD病史和CKD分期影响;KFRT关联在不同CKD分期中不一致。

临床怎么用

  • 在中重度CKD接受肾脏科照护的成人中,可考虑监测hsCRP以识别炎症相关心肾高风险患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND HYPOTHESIS: The burden and prognostic significance of inflammation in chronic kidney disease (CKD) remains poorly characterized, with prior studies yielding conflicting estimates of the association between elevated high-sensitivity C-reactive protein (hsCRP) and cardio-kidney outcomes. METHODS: Observational nationwide study of 23,008 adults with CKD stages 3-5 attending nephrology care and enrolled in the Swedish Renal Registry (2008-2023). Inflammation was assessed longitudinally via 94,500 repeated hsCRP registrations. Time-varying, cause-specific Cox models accounting for competing risks estimated associations with study outcomes, which included major adverse cardiovascular events (MACE), heart failure (HF) hospitalization, acute kidney injury (AKI), kidney failure requiring replacement therapy (KFRT) and all-cause mortality. Pre-defined stratifiers were atherosclerotic cardiovascular disease (ASCVD) history and CKD stage. RESULTS: Mean age was 71 years, 65% were male, and median estimated glomerular filtration rate was 25 mL/min/1.73 m². Median hsCRP was 4.0 (IQR 1.9-7.0) mg/L, and 75% of participants had hsCRP≥2. Over median 3.9 (IQR 2.0-6.7) years, hsCRP ≥2 mg/L was associated with higher rates of all outcomes: hazard ratio 1.20 (95% confidence interval 1.12-1.28) for MACE (n=5,480 events); 1.29 (1.22-1.37) for HF hospitalization (n=8,173); 1.28 (1.18-1.38) for AKI (n=3,943); 1.09 (1.02-1.15) for KFRT (n=6,177); and 1.43 (1.37-1.50) for mortality (n=12,645). In spline analyses, associations were steeper at lower hsCRP levels and flatter thereafter for all outcomes except KFRT, where the hsCRP-response relationship was relatively flat. Associations with MACE, HF, AKI and mortality were consistent regardless of ASCVD status and CKD stage. Associations with KFRT were inconsistent across CKD stages. CONCLUSION: In this nationwide cohort of adults with moderate to severe CKD receiving nephrology care, inflammation was common, and higher hsCRP levels were associated with adverse cardiovascular and kidney outcomes, as well as mortality. Although associations were less consistent for KFRT, these findings collectively support the utility of hsCRP monitoring in this population.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Mazhar F, Han M, Tuttle KR, et al. High sensitivity C-reactive protein and the risk of cardio-kidney outcomes in adults with moderate to severe chronic kidney disease: a nationwide study. Nephrol Dial Transplant. 2026. PMID: 42886061. doi:10.1093/ndt/gfag240

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。